MX393076B - Uso de derivados de ribósido de ácido nicotínico o ribósido de nicotinamida, y derivados reducidos de estos, como precursores que incrementan nad+ - Google Patents
Uso de derivados de ribósido de ácido nicotínico o ribósido de nicotinamida, y derivados reducidos de estos, como precursores que incrementan nad+Info
- Publication number
- MX393076B MX393076B MX2018012849A MX2018012849A MX393076B MX 393076 B MX393076 B MX 393076B MX 2018012849 A MX2018012849 A MX 2018012849A MX 2018012849 A MX2018012849 A MX 2018012849A MX 393076 B MX393076 B MX 393076B
- Authority
- MX
- Mexico
- Prior art keywords
- derivatives
- riboside
- nicotinic acid
- nicotinamide
- ribofuranosyl
- Prior art date
Links
- PUEDDPCUCPRQNY-ZYUZMQFOSA-N D-ribosylnicotinate Chemical class O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1[N+]1=CC=CC(C([O-])=O)=C1 PUEDDPCUCPRQNY-ZYUZMQFOSA-N 0.000 title abstract 3
- JLEBZPBDRKPWTD-TURQNECASA-O N-ribosylnicotinamide Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=C1 JLEBZPBDRKPWTD-TURQNECASA-O 0.000 title abstract 3
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 title abstract 2
- 235000020956 nicotinamide riboside Nutrition 0.000 title abstract 2
- 239000011618 nicotinamide riboside Substances 0.000 title abstract 2
- 239000002243 precursor Substances 0.000 title 1
- ILJSQTXMGCGYMG-UHFFFAOYSA-N triacetic acid Chemical compound CC(=O)CC(=O)CC(O)=O ILJSQTXMGCGYMG-UHFFFAOYSA-N 0.000 abstract 4
- IPXBSAHANXBVMU-OTVLKRCQSA-N 1-[(2R,3R,4R,5R)-3,4-diacetyl-3,4-dihydroxy-5-(1-hydroxy-2-oxopropyl)oxolan-2-yl]-2H-pyridine-3-carboxamide Chemical compound C(C)(=O)[C@@]1([C@@H](O[C@@H]([C@]1(O)C(C)=O)C(O)C(C)=O)N1CC(C(=O)N)=CC=C1)O IPXBSAHANXBVMU-OTVLKRCQSA-N 0.000 abstract 1
- QGZHUIXTGFZHJT-OTVLKRCQSA-N 1-[(2R,3R,4R,5R)-3,4-diacetyl-3,4-dihydroxy-5-(1-hydroxy-2-oxopropyl)oxolan-2-yl]-4H-pyridine-3-carboxamide Chemical compound C(C)(=O)[C@@]1([C@@H](O[C@@H]([C@]1(O)C(C)=O)C(O)C(C)=O)N1C=C(C(=O)N)CC=C1)O QGZHUIXTGFZHJT-OTVLKRCQSA-N 0.000 abstract 1
- JJICLWRQGDROCF-OTVLKRCQSA-N 1-[(2R,3R,4R,5R)-3,4-diacetyl-3,4-dihydroxy-5-(1-hydroxy-2-oxopropyl)oxolan-2-yl]-4H-pyridine-3-carboxylic acid Chemical compound C(C)(=O)[C@@]1([C@@H](O[C@@H]([C@]1(O)C(C)=O)C(O)C(C)=O)N1C=C(C(=O)O)CC=C1)O JJICLWRQGDROCF-OTVLKRCQSA-N 0.000 abstract 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 abstract 1
- 235000013361 beverage Nutrition 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 235000015872 dietary supplement Nutrition 0.000 abstract 1
- 230000037041 intracellular level Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229950006238 nadide Drugs 0.000 abstract 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 abstract 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 abstract 1
- 239000011664 nicotinic acid Substances 0.000 abstract 1
- 229960003512 nicotinic acid Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000004083 survival effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662325264P | 2016-04-20 | 2016-04-20 | |
| PCT/US2017/028673 WO2017184885A1 (en) | 2016-04-20 | 2017-04-20 | Use of nicotinic acid riboside or nicotinamide ribosite derivatives, and reduced derivatives thereof, as nad+increasing precursors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018012849A MX2018012849A (es) | 2019-08-29 |
| MX393076B true MX393076B (es) | 2025-03-24 |
Family
ID=60088650
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018012849A MX393076B (es) | 2016-04-20 | 2017-04-20 | Uso de derivados de ribósido de ácido nicotínico o ribósido de nicotinamida, y derivados reducidos de estos, como precursores que incrementan nad+ |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10183036B2 (enExample) |
| EP (1) | EP3445359B8 (enExample) |
| JP (3) | JP7089480B2 (enExample) |
| KR (1) | KR20190008246A (enExample) |
| CN (1) | CN109640984A (enExample) |
| AU (2) | AU2017254657A1 (enExample) |
| BR (1) | BR112018071573A2 (enExample) |
| CA (1) | CA3021571C (enExample) |
| ES (1) | ES2948968T3 (enExample) |
| MX (1) | MX393076B (enExample) |
| NZ (1) | NZ747693A (enExample) |
| WO (1) | WO2017184885A1 (enExample) |
| ZA (1) | ZA201807736B (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3322419B1 (en) * | 2015-07-15 | 2025-09-03 | Cornell University | Syntheses, activities, and methods of use of dihydronicotinamide riboside derivatives |
| EA035664B1 (ru) | 2015-08-05 | 2020-07-23 | МЕТРО ИНТЕРНЭШНЛ БАЙОТЕК, ЭлЭлСи | Производные никотинамидмононуклеотида и их применение для лечения заболевания или расстройства, связанного с биосинтезом над+ |
| GB2542881B (en) | 2015-10-02 | 2020-01-01 | Carr Andrew | Crystal forms of ß-nicotinamide mononucleotide |
| CA3045876A1 (en) | 2016-11-11 | 2018-05-17 | The Queen's University Of Belfast | Scalable syntheses of nicotinoyl ribosides and reduced nic otinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof |
| BR112019010607B1 (pt) | 2016-11-29 | 2023-10-31 | University Of Iowa Research Foundation | Uso de precursores de nad e composição compreendendo os referidos precursores |
| US11071747B2 (en) | 2016-11-29 | 2021-07-27 | University Of Iowa Research Foundation | Use of NAD precursors for breast enhancement |
| WO2018191771A1 (en) * | 2017-04-18 | 2018-10-25 | Victor Chang Cardiac Research Institute | Detection and treatment of congenital malformations |
| SG11201912267SA (en) | 2017-06-19 | 2020-01-30 | Gangadhara Ganapati | Nicotinamide riboside derivatives and their uses |
| AU2019214858B2 (en) * | 2018-01-30 | 2023-02-02 | Metro International Biotech, Llc | Nicotinamide riboside analogs, pharmaceutical compositions, and uses thereof |
| JP2021525279A (ja) * | 2018-05-22 | 2021-09-24 | ジャンプスタート ファーティリティ ピーティーワイ リミテッド | 抗加齢剤としてのニコチン酸リボシドのアミノ酸塩 |
| US11833167B2 (en) | 2018-12-17 | 2023-12-05 | Mitopower Llc | Nicotinyl riboside compounds and their uses |
| CN113727987A (zh) * | 2019-02-21 | 2021-11-30 | 可劳迈戴斯有限公司 | 烟酰胺核苷、烟酸核苷、还原型烟酰基核苷化合物和烟酰基核苷化合物衍生物在制品的用途 |
| US11939348B2 (en) | 2019-03-22 | 2024-03-26 | Metro International Biotech, Llc | Compositions comprising a phosphorus derivative of nicotinamide riboside and methods for modulation of nicotinamide adenine dinucleotide |
| JP7610531B2 (ja) * | 2019-06-05 | 2025-01-08 | ソシエテ・デ・プロデュイ・ネスレ・エス・アー | 腎疾患を治療又は予防するための還元型ニコチンアミドリボシド |
| EP3980028A1 (en) * | 2019-06-05 | 2022-04-13 | Société des Produits Nestlé S.A. | Reduced nicotinamideribosides for treating/preventing skeletal muscle disease |
| CN113840612A (zh) * | 2019-06-05 | 2021-12-24 | 雀巢产品有限公司 | 用于治疗/预防肝脏疾病的还原型烟酰胺核糖核苷 |
| CN110973260A (zh) * | 2019-12-11 | 2020-04-10 | 杨力 | 一种含有烟酰胺核糖苷的牛奶及其制备方法与应用 |
| US20230000888A1 (en) | 2019-12-19 | 2023-01-05 | Leibniz-Institut Für Alternsforschung - Fritz-Lipmann-Institut E.V. (Fli) | Nad-precursors and dietary restriction for treating age related medical conditions |
| WO2021180732A1 (en) * | 2020-03-09 | 2021-09-16 | Société des Produits Nestlé S.A. | Compositions and methods containing reduced nicotinamide riboside for prevention and treatment of neurological diseases and conditions |
| WO2021180731A1 (en) * | 2020-03-09 | 2021-09-16 | Société des Produits Nestlé S.A. | Compositions and methods containing reduced nicotinamide riboside for prevention and treatment of cardiovascular diseases and conditions |
| EP4117681A1 (en) * | 2020-03-09 | 2023-01-18 | Société des Produits Nestlé S.A. | Compositions and methods containing reduced nicotinamide riboside for prevention and treatment of pancreatic diseases and conditions |
| US20230095103A1 (en) * | 2020-03-09 | 2023-03-30 | Societe Des Produits Nestle S.A. | Compositions and methods containing reduced nicotinamide riboside for prevention and treatment of lung diseases and conditions |
| CN114561342B (zh) * | 2020-11-27 | 2024-12-20 | 西安交通大学医学院第一附属医院 | Nad信号通路激动剂在体外胚胎培养中的应用 |
| CN115669929A (zh) * | 2021-01-15 | 2023-02-03 | 江苏恒正合生命科学有限公司 | 辅助改善记忆的功能性食品其制备方法 |
| US20240245714A1 (en) * | 2021-05-05 | 2024-07-25 | Societe Des Produits Nestle S.A. | Composition and methods using combination of narh and nr to produce intracellular nicotinamide adenine dinucleotide (nad+) |
| KR20240020716A (ko) | 2021-05-27 | 2024-02-15 | 메트로 인터내셔널 바이오테크 엘엘씨 | 니코틴산 모노뉴클레오타이드 및 이의 에스터의 결정질 고체 및 제조 및 사용 방법 |
| US20230014055A1 (en) * | 2021-06-18 | 2023-01-19 | Mitopower Llc | Treatment of Immune-Related Disorders, Kidney Disorders, Liver Disorders, Hemolytic Disorders, and Oxidative Stress-Associated Disorders Using NRH, NARH and Reduced Derivatives Thereof |
| JP7111878B1 (ja) | 2021-10-27 | 2022-08-02 | 旭化成ファーマ株式会社 | ニコチンアミドモノヌクレオチドの製造方法 |
| US20240415862A1 (en) * | 2021-10-27 | 2024-12-19 | Elysium Health Inc. | Methods for treatment of menopausal syndromes |
| WO2023150072A1 (en) | 2022-02-01 | 2023-08-10 | Sinclair David A | Compositions and methods for the preservation of plant matter |
| EP4472993A2 (en) * | 2022-02-04 | 2024-12-11 | Elysium Health, Inc. | Ribose linkers and conjugates thereof |
| US12116382B2 (en) | 2022-11-28 | 2024-10-15 | Hongene Biotech Corporation | Functionalized N-acetylgalactosamine analogs |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7022680B2 (en) | 2002-05-30 | 2006-04-04 | Albert Einstein College Of Medicine Of Yeshiva University | Inhibitors of ADP-ribosyl transferases, cyclases, and hydrolases |
| US7977049B2 (en) | 2002-08-09 | 2011-07-12 | President And Fellows Of Harvard College | Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
| US7927859B2 (en) * | 2003-08-22 | 2011-04-19 | Rice University | High molar succinate yield bacteria by increasing the intracellular NADH availability |
| AU2005211773B2 (en) | 2004-02-10 | 2009-06-25 | Trustees Of Dartmouth College | Nicotinamide riboside kinase compositions and methods for using the same |
| AU2005257883A1 (en) | 2004-06-04 | 2006-01-05 | Washington University | Methods and compositions for treating neuropathies |
| EP3369738B1 (en) * | 2005-11-18 | 2020-05-20 | Cornell Research Foundation, Inc. | Method for making nicotinoyl ribosides and nicotinamide beta-riboside |
| GB201313465D0 (en) | 2013-07-29 | 2013-09-11 | Queens University Of The Belfast | Methods of preparing nicotinamide riboside and derivatives thereof |
| ES2925879T3 (es) * | 2013-10-30 | 2022-10-20 | Chromadex Inc | Composiciones de ribósido de nicotinamida para uso tópico en el tratamiento de afecciones de la piel |
| KR20170008320A (ko) * | 2014-06-06 | 2017-01-23 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | 니코틴아미드 리보시드 유사체 및 그의 제약 조성물 및 용도 |
| MX390185B (es) * | 2015-03-16 | 2025-03-20 | Chromadex Inc | Composiciones de acido nicotinico ribosido o de nicotinamida ribosido, derivados reducidos de los mismos, y su uso. |
| EP3322419B1 (en) | 2015-07-15 | 2025-09-03 | Cornell University | Syntheses, activities, and methods of use of dihydronicotinamide riboside derivatives |
| EA035664B1 (ru) | 2015-08-05 | 2020-07-23 | МЕТРО ИНТЕРНЭШНЛ БАЙОТЕК, ЭлЭлСи | Производные никотинамидмононуклеотида и их применение для лечения заболевания или расстройства, связанного с биосинтезом над+ |
| US10857172B2 (en) * | 2016-04-14 | 2020-12-08 | Chromadex, Inc. | Use of nicotinamide riboside, nicotinic acid riboside, and nicotinamide mononucleotide, reduced nicotinyl compounds, and nicotinoyl compound derivatives in infant formula for healthy development |
-
2017
- 2017-04-20 NZ NZ747693A patent/NZ747693A/en unknown
- 2017-04-20 CN CN201780038245.5A patent/CN109640984A/zh active Pending
- 2017-04-20 WO PCT/US2017/028673 patent/WO2017184885A1/en not_active Ceased
- 2017-04-20 CA CA3021571A patent/CA3021571C/en active Active
- 2017-04-20 BR BR112018071573-5A patent/BR112018071573A2/pt not_active Application Discontinuation
- 2017-04-20 AU AU2017254657A patent/AU2017254657A1/en not_active Abandoned
- 2017-04-20 KR KR1020187033413A patent/KR20190008246A/ko not_active Ceased
- 2017-04-20 JP JP2018554765A patent/JP7089480B2/ja active Active
- 2017-04-20 ES ES17786649T patent/ES2948968T3/es active Active
- 2017-04-20 EP EP17786649.8A patent/EP3445359B8/en active Active
- 2017-04-20 US US15/492,952 patent/US10183036B2/en active Active
- 2017-04-20 MX MX2018012849A patent/MX393076B/es unknown
-
2018
- 2018-11-16 ZA ZA2018/07736A patent/ZA201807736B/en unknown
-
2021
- 2021-07-16 JP JP2021117648A patent/JP2021176871A/ja active Pending
-
2022
- 2022-08-22 AU AU2022221384A patent/AU2022221384C1/en active Active
- 2022-10-19 JP JP2022167877A patent/JP7493007B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US10183036B2 (en) | 2019-01-22 |
| EP3445359A1 (en) | 2019-02-27 |
| JP2019514874A (ja) | 2019-06-06 |
| CA3021571C (en) | 2023-01-03 |
| WO2017184885A8 (en) | 2023-08-24 |
| JP7493007B2 (ja) | 2024-05-30 |
| WO2017184885A1 (en) | 2017-10-26 |
| US20170304338A1 (en) | 2017-10-26 |
| AU2022221384B2 (en) | 2023-03-23 |
| ES2948968T3 (es) | 2023-09-22 |
| EP3445359C0 (en) | 2023-06-07 |
| NZ747693A (en) | 2023-07-28 |
| CN109640984A (zh) | 2019-04-16 |
| MX2018012849A (es) | 2019-08-29 |
| ZA201807736B (en) | 2020-05-27 |
| BR112018071573A2 (pt) | 2019-02-12 |
| KR20190008246A (ko) | 2019-01-23 |
| AU2022221384A1 (en) | 2022-09-22 |
| CA3021571A1 (en) | 2017-10-26 |
| EP3445359B1 (en) | 2023-06-07 |
| JP2021176871A (ja) | 2021-11-11 |
| EP3445359A4 (en) | 2019-12-25 |
| AU2022221384C1 (en) | 2023-08-03 |
| JP2023002685A (ja) | 2023-01-10 |
| JP7089480B2 (ja) | 2022-06-22 |
| AU2017254657A1 (en) | 2018-11-15 |
| EP3445359B8 (en) | 2023-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX393076B (es) | Uso de derivados de ribósido de ácido nicotínico o ribósido de nicotinamida, y derivados reducidos de estos, como precursores que incrementan nad+ | |
| MX390185B (es) | Composiciones de acido nicotinico ribosido o de nicotinamida ribosido, derivados reducidos de los mismos, y su uso. | |
| EA201890435A1 (ru) | Производные никотинамидмононуклеотида и их применение | |
| WO2020131578A3 (en) | Nicotinyl riboside compounds and their uses | |
| MX2021009652A (es) | Composiciones de ribosido de nicotinamida para uso topico en el tratamiento de afecciones de la piel. | |
| BR112012020742A2 (pt) | derivados de pirazolo piperidina como inibidores de nadph oxidase. | |
| MX2015005949A (es) | Nucleosidos que contienen aza-azucar antiviral. | |
| BR112012030818A2 (pt) | "derivados de ácido c-3 betulínico modificado como inibidores da maturação do hiv" | |
| PH12014501134A1 (en) | 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication | |
| MY189761A (en) | Quinazoline derivatives used to treat hiv | |
| BR112018007153A2 (pt) | reajuste de caminhos biológicos de defesa contra e reparo de danos causados por envelhecimento humano | |
| PH12016501567B1 (en) | 4`-difluoromethyl substituted nucleoside derivatives as inhibitors of influenza rna replication | |
| BR112015021549A2 (pt) | inibidores de piridina cinase cdk9 | |
| MX361652B (es) | Análogos de cortistatina y síntesis y usos de los mismos. | |
| BR112014002245A2 (pt) | derivados de piridin-2(1h)-ona como inibidores de jak | |
| DK2007429T3 (da) | Oralt præparat med gavnlige cardiovaskulære virkninger indeholdende berberin | |
| BR112012020736A2 (pt) | derivados de pirazolo diperidina como inibidores de nadph oxidase. | |
| UY31294A1 (es) | Derivados de tetrahidrocarbozol, métodos para obtenerlos, formulaciones que los contienen y usos de los mismos | |
| UA115357C2 (uk) | Похідні піридин-4-ілу | |
| DOP2010000342A (es) | Compuestos conteniendo nitrogeno triciclico y sus usos como antibacteriales | |
| AU2017356887A8 (en) | sGC stimulators | |
| MX2012007896A (es) | Derivados de piridino-piridinonas arilsulfonamidas, su preparacion y su uso en terapeutica. | |
| BR112016005509A8 (pt) | método de preparação de um extrato de sementes de urucum (anato), composição, extrato vegetal, e composição farmacêutica | |
| UY34009A (es) | ?uso de receptor de a2b adenosina para tratar la insuficiencia cardíaca y la arritmia en pacientes posinfarto de miocardio?. | |
| AU2017241626A1 (en) | Viable cell compositions, and methods related to same |